Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Quantum-Si Incorporated is a life sciences technology company focused on developing next-generation protein sequencing platforms. The company operates within the biotechnology, life sciences tools, and proteomics industries, aiming to enable scalable, single-molecule protein analysis for research and applied markets. Its core value proposition is the ability to directly sequence proteins—addressing limitations of traditional mass spectrometry–based proteomics in sensitivity, accessibility, and scalability.
The company’s primary revenue drivers are its proprietary Platinum® protein sequencing platform, consumable sequencing chips, reagents, and related software. Quantum-Si primarily serves academic researchers, biopharmaceutical companies, and biotechnology firms engaged in drug discovery, translational research, and biomarker development. Founded in 2013, the company evolved from early-stage R&D into a publicly traded entity following its merger with a special purpose acquisition company in 2021, enabling broader commercialization of its sequencing technology.
Business Operations
Quantum-Si operates as a single-reportable-segment company focused on developing and commercializing protein sequencing systems and consumables. Revenue is generated through the sale of instrument systems, recurring consumables, and associated service and support offerings. While commercial revenue remains limited, the company emphasizes expanding its installed base to drive long-term consumables adoption.
Operations include in-house development of semiconductor-based sequencing chips, biochemical reagents, and proprietary software and data analytics. Manufacturing is a combination of internal processes and third-party suppliers. Quantum-Si does not report significant joint ventures and conducts most R&D internally, maintaining control over its core intellectual property and platform architecture.
Strategic Position & Investments
Quantum-Si’s strategy centers on expanding adoption of its Platinum® platform, improving throughput and accuracy, and lowering barriers to protein sequencing for a broader research audience. Growth initiatives include ongoing platform enhancements, expanded consumables offerings, and deeper engagement with pharmaceutical and academic collaborators to validate real-world applications.
The company has invested heavily in internal R&D rather than large-scale acquisitions, prioritizing platform refinement over inorganic growth. Its strategic focus includes emerging areas such as single-molecule proteomics, functional protein analysis, and applications supporting precision medicine and drug development. Public disclosures indicate no material acquisitions of operating companies to date; data on additional portfolio investments beyond core operations is inconclusive based on available public sources.
Geographic Footprint
Quantum-Si is headquartered in North America, with its principal offices and laboratories located in the United States. The company’s commercial activities are primarily U.S.-based, reflecting its early-stage commercialization and concentration of life sciences customers domestically.
Internationally, Quantum-Si serves customers in Europe and parts of Asia-Pacific through direct sales efforts and distribution arrangements. While global reach is expanding, international operations remain a smaller portion of overall activity, with limited physical infrastructure outside the U.S. as of the most recent public disclosures.
Leadership & Governance
Quantum-Si was founded by Jonathan Rothberg, who also serves as Executive Chairman and is a recognized figure in DNA sequencing and life sciences innovation. The leadership team emphasizes long-term platform development, scientific rigor, and democratizing access to advanced proteomics technologies.
Key executives include:
- Jeff Hawkins – President and Chief Executive Officer
- Jonathan Rothberg – Executive Chairman
- Eric Colson – Chief Financial Officer
- Molly Hall – Chief Operating Officer
- Claus Wallentin – Chief Technology Officer
The company is governed by a board with experience across biotechnology, semiconductors, and public company oversight, reflecting a strategic vision focused on technological differentiation and disciplined commercialization.